Original Article
Modern Pathology (2008) 21, 31–38; doi:10.1038/modpathol.3800971; published online 21 September 2007
Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans
Presented in part at the 96th United States and Canadian Academy of Pathology Annual Meeting, San Diego, CA, USA, March 2007.
Mikhail Lisovsky1, Mai P Hoang1, Karen A Dresser1, Payal Kapur2, Jag Bhawan3 and Meera Mahalingam1
- 1Department of Pathology, UMass Medical School, Worcester, MA, USA
- 2University of Texas Southwestern Medical Center, Dallas, TX, USA
- 3Department of Dermatology, Boston University School of Medicine, Boston, MA, USA
Correspondence: Dr M Mahalingam, MD, PhD, FRCPath, Dermatopathology Section, Department of Dermatology, Skin Pathology Laboratory, Boston University School of Medicine, 609 Albany Street, J-308, Boston, MA 02118, USA. E-mail: mahalinm@bu.edu
Received 31 May 2007; Revised 18 July 2007; Accepted 1 August 2007; Published online 21 September 2007.
Abstract
More recent techniques to characterize the genetic profile of soft-tissue tumors include the use of gene arrays. Using this technique, Apolipoprotein D (Apo D), a 33-kDa glycoprotein component of high-density lipoprotein, has been found to be highly expressed in dermatofibrosarcoma protuberans. To corroborate these results, we sought to ascertain the utility of Apo D by investigating its sensitivity and specificity in a variety of CD34-positive and CD34-negative cutaneous neoplasms including superficial acral fibromyxoma, sclerotic fibromas, and cellular dermatofibromas. Of interest, we found absence of Apo D expression in all four cases of superficial acral fibromyxoma. Of the remaining CD34-positive lesions, Apo D expression was noted in 35/36 (97%) cases of dermatofibrosarcoma protuberans, 3/5 (60%) giant-cell fibroblastomas, 4/4 (100%) sclerotic fibromas, 8/8 (100%) neurofibromas, and 1/1 (100%) solitary fibrous tumor. Of the CD34-negative lesions, Apo D expression was noted in 2/22 (9%) regular dermatofibroma, 23/45 (51%) cellular dermatofibroma, 10/10 (100%) malignant fibrous histiocytoma, 9/10 (90%) atypical fibroxanthoma, 7/8 (86%) cellular neurothekeoma, 9/9 (100%) malignant melanoma, 8/8 (100%) melanocytic nevi (100%), 0/2 superficial angiomyxoma, 0/15 fibromatosis, 0/1 nodular fasciitis, and 1/2 (50%) desmoplastic fibroblastomas. In summary, our findings indicate that Apo D expression is not specific to dermatofibrosarcoma protuberans. Its principal use as an immunohistochemical adjunct lies in its utility in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. Although strong positive staining of Apo D in a markedly atypical fibrohistiocytic lesion is suggestive of atypical fibroxanthoma and/or malignant fibrous histiocytoma, further studies with the inclusion of other atypical spindled cell neoplasms are required to conclusively prove the same.
Keywords:
apolipoprotein D, Apo D, CD34, superficial acral fibromyxoma, dermatofibrosarcoma protuberans
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Retinoid signalling in the development of the central nervous system
Nature Reviews Neuroscience Review (01 Nov 2002)
RESEARCH
Nuclear beta-catenin in mesenchymal tumors
Modern Pathology Original Article
Modern Pathology Original Article
Modern Pathology Original Article
Modern Pathology Letter

